Why Waters Corporation stock remains on buy lists - Chart Signals & Low Risk Entry Point Tips

FierceBiotechAffibody gets izokibep ‘back on track’ while seeking ‘new home’ after drug’s Acelyrin rejection

FierceBiotechInsulet debuts latest enhancements to popular Omnipod insulin delivery system

PharmaVoiceBMS under pressure in schizophrenia; Summit/Akeso on a winning streak

Promega BlogMeasuring What Matters in Metabolic Research: A Bioluminescent Toolkit

BioWorldNME Digest: Q1 2026

FierceBiotechChutes & Ladders—AstraZeneca adds FDA cell and gene veteran

BioWorldNew York University identifies new analogues of mannose-6-phosphate

BioWorldAvelos Therapeutics synthesizes new PARG inhibitors

BioWorldSimcere Zaiming Pharmaceutical discovers new MAPK inhibitors

LabiotechEight oncology deals in 2026 spotlight where industry leaders are betting big

Endpoints NewsFulcrum lays off majority of staff; Seres extends runway into 2027

PharmaVoiceGSK, Takeda and others notch key clinical wins in tough-to-treat diseases